Portal de Periódicos da CAPES

Mineralocorticoid receptor antagonists for heart failure: a real‐life observational study

2018; Wiley; Volume: 5; Issue: 3 Linguagem: Inglês

10.1002/ehf2.12244

2055-5822

Noemi Bruno, Gianfranco Sinagra, Stefania Paolillo, Alice Bonomi, Ugo Corrà, Massimo Piepoli, Fabrizio Veglia, Elisabetta Salvioni, Rocco Lagioia, Marco Metra, Giuseppe Limongelli, Gaia Cattadori, Angela Beatrice Scardovi, Valentina Carubelli, Domenico Scrutino, Roberto Badagliacca, Marco Guazzi, Rosa Raimondo, Piero Gentile, Damiano Magrì, Michele Correale, Gianfranco Parati, Federica Re, Mariantonietta Cicoira, Maria Frigerio, Maurizio Bussotti, Carlo Vignati, Fabrizio Oliva, Alessandro Mezzani, Giuseppe Vergaro, Andrea Di Lenarda, Claudio Passino, Susanna Sciomer, Giuseppe Pacileo, Roberto Ricci, Mauro Contini, Anna Apostolo, Pietro Palermo, Massimo Mapelli, Cosimo Carriere, Francesco Clemenza, Simone Binno, Romualdo Belardinelli, Carlo Lombardi, Pasquale Perrone Filardi, Michele Emdin, Piergiuseppe Agostoni,

Cardiovascular Function and Risk Factors

Mineralocorticoid receptor antagonists (MRAs) have been demonstrated to improve outcomes in reduced ejection fraction heart failure (HFrEF) patients. However, MRAs added to conventional treatment may lead to worsening of renal function and hyperkalaemia. We investigated, in a population-based analysis, the long-term effects of MRA treatment in HFrEF patients.